One platform.
Two frontiers in oncology.
LifePulse Corporation builds the IntelliPulse® electroporation platform — intratumoral chemotherapy, gene therapy delivery, and tumor ablation in one system. Already treating cancer in veterinary clinics today, and advancing toward human melanoma trials.
Inside LifePulse Bioscience
A look at the VetPulse 2000 platform and the IntelliPulse® technology behind it, direct from our veterinary team.
Watch on YouTubeThe veterinary and human divisions are one company — now the site reads that way too.
LifePulse's veterinary oncology business (formerly lifepulsebio.com) and its human oncology science (formerly lifepulse.co) lived on two disconnected websites. One unified, professional presence matters as the company advances its FDA pathway and talks with strategic acquirers.
- Veterinary and human oncology content combined under one domain
- One leadership and board story, referenced everywhere
- A single technology narrative for IntelliPulse®, shared across both divisions
- Consumables ordering, kept separate from capital equipment sales
Cancer treatment is still imprecise, toxic, and inefficient
Scroll through the three approaches ↓
Systemic chemotherapy
Used on roughly 2 million new U.S. patients a year. It kills cancer cells, but circulates through the entire body — side effects patients can barely tolerate.
Intratumoral chemotherapy
Treating the tumor directly reduces systemic exposure, but alone it doesn't reach metastatic disease elsewhere, and remains highly toxic locally.
Intratumoral gene therapy
Promising for metastatic cancers, but delivery is inconsistent — tumors aren't uniform, and higher energy risks damaging the therapy before it works. This is the gap IntelliPulse is built to close.
IntelliPulse®: a quantum advance for pulsed electrical fields
Electroporation uses a brief electric field to temporarily open pores in a cell's membrane. While open, a chemotherapy agent or therapeutic gene moves directly inside; afterward, the membrane reseals — the cell continues carrying its new payload, or does not survive at all.
Built on more than three decades of pulsed electrical field research, IntelliPulse packages that principle into one adaptive, multi-modal platform — with moderate heat, real-time impedance feedback, and addressable electrodes.
Low-Voltage EP
150–450V, versus 1,300V in legacy systems — less than half the energy of any comparable device.
Tumor Sense Technology
Real-time impedance sensing auto-adjusts pulse parameters to the tissue in front of it.
Multi-Modal Platform
Intratumoral chemotherapy, gene electrotransfer, and irreversible electroporation (ablation) — one system.
Two divisions, one IntelliPulse® platform
The same technology serves two very different markets today: a veterinary business already generating revenue, and a human oncology program opening a market nearly 190x larger.
Built alongside teaching hospitals and veterinary practices
A growing list of veterinary colleges and practices working with LifePulse Bioscience — with more partners added regularly.
Kansas State University
University of Illinois
Foxhall Equine
Concise Engineering
Foxhall EquineKansas State UniversityUniversity of IllinoisFoxhall EquineConcise EngineeringFoxhall EquineSee IntelliPulse® in your clinic or lab
Talk with our team about the VetPulse 2000 platform, consumable ordering, or partnering on human oncology research.
Cancer treatment veterinary clinics can afford to offer
The VetPulse 2000 platform delivers intratumoral chemotherapy, gene therapy, and ablation for companion animals and horses — at roughly a tenth of the cost of radiotherapy, with minimal anesthesia and hundreds of successful treatments since March 2022.
Built by the scientists who pioneered PEF technology
Dr. Richard Heller and Dr. Mark Jaroszeski have spent three decades perfecting pulsed electrical field technology, producing more than 100 patents and nearly 100 publications along the way. The VetPulse 2000 is the result — able to detect tissue impedance in real time while using less than half the energy of any other device on the market.
- The only US engineered and manufactured device of its kind
- Real-time impedance feedback confirms delivery as it happens
- Reduced risk of healthy tissue damage vs. legacy high-voltage systems
- Simple enough for daily clinical use, with practitioner peace of mind built in
Procedure-specific, sterile-packed electrodes
Plate Electrodes
A 7.5mm gap, ideal for treating partially or fully resected tumors to eliminate microscopic disease.
Needle Electrodes
Available in three configurations — 7.5mm gap 10-needle, 5.0mm gap 10-needle, and 5mm gap 4-needle arrays — ideal for gross disease or scars, with or without penetration.
Contact Pin Electrodes
Available in 2025. Designed for larger resected areas, with particular utility in equine medicine.
All electrodes are surgically packed for maximum efficacy and sterility per patient, and designed to comply with 2022 ESOPE single-use protocols.
A broad range of tumor types, across species
Companion animals
Equine
Also used for enhanced delivery of immunotherapy and vaccines. Full indication guidance available through your account representative.
Proven efficacy in oral tumors
Clinical case documentation from LifePulse's veterinary case files. Additional case photography available on request through your account representative.
Razor & blade economics
Distribution runs through Patterson Veterinary alongside direct sales, with a scalable manufacturing partnership supporting growth toward full veterinary scale-up.
Ready to bring IntelliPulse to your clinic?
Our team can walk your practice through the platform, pricing, and onboarding.
Request a DemoA de-risked path from the clinic to human melanoma
LifePulse is building on veterinary traction — and published electroporation research from groups like OncoSec, Inovio, and Moffitt Cancer Center — to bring IntelliPulse to human patients, beginning with pancreatic tumor ablation and melanoma.
What's next on the platform
LifePulse IntelliPulse® S
In development for use in 2026, purpose-built for the surgical suite. This is the device planned for LifePulse's first human clinical trial — ablating pancreatic tumors — and intended for 510(k) filing using the NanoKnife® as a predicate device.
Gelonin
An exceptionally large-molecule protein deliverable only with the IntelliPulse system — non-toxic unless delivered directly into a cell.
VetPulse® 3000
Planned to be the first FDA-cleared-for-human-use electroporation device of its kind.
Additional Therapeutics
In discussions with a California-based pharmaceutical firm to bring six additional drugs and drug combinations uniquely suited for pulsed-electrical-field delivery.
Three treatment modes, one platform
Scroll through the three modes ↓
Drug Delivery
Used for intratumoral chemotherapy. Cells absorb the drug through temporarily opened pores and die from the drug's action shortly after.
Gene Delivery
Cells take up a therapeutic gene and go on to produce the therapeutic molecule that gene encodes — the mechanism behind LifePulse's human melanoma and pancreatic programs.
Ablation
Deliberate over-pulsation is used as irreversible electroporation, directly disabling targeted cells — for soft-tissue ablation and palliative care.
Building on a growing body of electroporation research
LifePulse's human program builds on work by others advancing electroporation-based chemotherapy and gene therapy, including research from OncoSec, Inovio, Neon, IGEA, and ICHOR. Early Phase I results from Moffitt Cancer Center researchers using this class of approach have been encouraging, with treated lesions showing visible clearance while untreated lesions in the same patients persisted.
An NIH/NCI grant is directly funding LifePulse's veterinary melanoma animal study, providing early validation of the human-relevant science ahead of a formal clinical program.
Clinical trial targets
Planned exit strategy: dual-track execution
Scroll to move through the roadmap →
- Achieve veterinary breakeven milestone
- Scale Patterson distribution & manufacturing
- Complete NIH melanoma study
- Complete build of FDA-compliant device
- Pursue breakthrough designation
- Expand veterinary business toward a $10M+ run rate
- Human safety trial at Tampa General Cancer Institute
- First-in-human pancreatic tumor ablation
- Pursue strategic pharma partnership
- Secure strategic partnership
- Position for strategic acquisition
- Regulatory clarity across both divisions
Regulatory strategy centers on a 510(k) pathway, informed by predicate devices already used by Boston Scientific, Abbott, Medtronic, and Johnson & Johnson.
Peer-reviewed & supporting research
Hover a card to preview, then download the full paper.
Impedance-based feedback in electroporation
Hover to previewAtkins et al. — Bioelectrochemistry. Examines how real-time impedance measurement can confirm therapeutic delivery during electroporation procedures.
Download PDFIn-vitro thermal effects of moderate-heat EP
Hover to previewDonate et al. — Bioelectrochemistry, 2015. Studies how moderate heat (43°C) during electroporation affects treatment tolerability and outcomes.
Download PDFModerate-heat EP in squamous cell carcinoma
Hover to previewEdelblute et al. Investigates moderate-heat electroporation as a treatment approach specifically for squamous cell carcinoma.
Download PDFGene transfer for HBsAg vaccine delivery
Hover to previewEdelblute et al. Explores electroporation-mediated gene transfer as a delivery method for hepatitis B surface antigen (HBsAg) vaccination.
Download PDFAdditional publications and the full case study library are available to qualified research and clinical partners on request.
Interested in the human oncology program?
Clinicians, researchers, and strategic partners can reach our team directly.
Contact the Research TeamHow IntelliPulse® works
One electroporation platform, three clinical applications, shared across both the veterinary and human oncology divisions.
What is reversible electroporation?
A brief electric field induces a voltage across the cell membrane. While active, the membrane temporarily opens — letting genes or drugs move inside. Push the pulse parameters further, past what the membrane can recover from, and the same mechanism becomes irreversible electroporation, used deliberately for tumor ablation.
Before pulse
Cell membrane intact, drugs and genes remain outside.
During E-field
Membrane pores temporarily open under the electric pulse.
After pulse
Membrane reseals — the cell now carries its new payload.
A ~20-minute in-clinic procedure
- The therapeutic is injected intratumorally in linear retrotracing lines every 6mm from the mass perimeter, withdrawing the needle while injecting to saturate the tumor.
- Tissue temperature displays live during the heating phase; at 43°C the device beeps once — 30 seconds to pulse.
- The device pulses (two beeps), once or several times based on real-time tissue impedance feedback — never a single blind pulse.
- Three beeps signal the desired impedance drop is reached — maximum delivery achieved, move to the next area.
- Pulse roughly a 1cm margin around the tumor; once complete, cycle back for the next patient.
Tracking treatment with Petlynx
For the first time, owners and veterinarians can track treatment, share photos, and store treatment data in the cloud through the Petlynx app — turning real-time impedance confirmation into visible, shareable progress.
- Owners upload photos to track healing over time
- Impedance confirmation removes the guesswork on delivery
- De-identified data feeds future A.I.-driven precision treatment
Superior on every axis that matters
150V vs. 1,300V legacy
Less than half the energy of any comparable device — lower pain scores and less need for heavy anesthesia.
Real-Time impedance feedback
Tumor Sense technology automatically adjusts pulse parameters to tissue characteristics for safer, consistent efficacy.
~1/10th procedure cost
A worldwide exclusive license combined with a much lower cost structure creates a significant market-access advantage.
Competitive landscape
No targeted, enhanced cellular-delivery treatment of this kind has yet reached commercial scale in the United States.
A defensible patent position
LifePulse holds a worldwide exclusive license to use and sublicense a patent portfolio built on more than three decades and $35M of research funding by the technology's founding scientists, Dr. Richard Heller and Dr. Mark Jaroszeski — whose combined body of work spans 100+ patents and nearly 100 publications.
Separable patent families
Separate human and veterinary patent families, allowing either division to be spun off independently.
Worldwide trademark protection
IntelliPulse® and LifePulse® are protected trademarks across all target markets.
Trade secret algorithms
Proprietary IntelliPulse® impedance-sensing algorithms held as protected trade secrets.
About LifePulse Corporation
Founded in Tampa, Florida, LifePulse is dedicated to making cellular-delivery cancer treatment precise, affordable, and accessible — first in veterinary medicine, and now advancing toward human oncology.
Founded on three decades of overlooked science
Gary Strange founded LifePulse Corporation in 2018, bringing more than 30 years of business leadership to a technology with roots in pulsed electrical field research dating back three decades. A combined 100+ years of collective research by the platform's founding scientists produced the patent portfolio LifePulse acquired in 2020 — just before pulsed electrical fields became one of the most closely watched technologies in biotech.
The company built its early commercial base in veterinary oncology through LifePulse Bioscience, the division producing revenue today, while laying the regulatory groundwork to bring the same platform to human patients.
Mission
Make this life-changing technology available to the U.S. first, then the world — beginning with pancreatic tumor trials, changing outcomes for patients who need better options now.
Vision
A single, unified platform recognized across both veterinary and human oncology — proof that one technology can serve two markets at very different stages.
Path forward
Presenting one coherent, professional company — not two disconnected websites — as LifePulse prepares for a planned FDA 510(k) submission and strategic conversations.
Founded & IP acquired
Gary Strange founds LifePulse; the founding scientists' pulsed electrical field patents are acquired.
Commercial launch
VetPulse 2000 launches; hundreds of animals treated; $424K 2025 revenue; NIH/NCI awards a $2M grant.
Scaling & new governance
Patterson Veterinary partnership; new board members added; unified website launches.
Experienced management driving execution and growth across LifePulse's veterinary and human oncology divisions.
Bob Roda
Chief Executive OfficerBob brings extensive experience and a proven record of success leading teams and building businesses across MedTech, diagnostics, and pharmaceuticals. He also serves on LifePulse's Board of Directors.
Dr. Chris Slachta, Ph.D., M.B.A.
Chief Operating OfficerChris leads operations with a guiding principle that pairs scientific rigor with operational excellence, driving growth and execution across the healthcare spectrum.
Bill Gilmour
Chief Financial OfficerA seasoned finance executive with nearly a decade in biomedical technology and extensive M&A and Fortune 500 experience — Bill helped launch LifePulse to commercialization in under five years.
Shawn Walker
Chief Commercial OfficerShawn brings significant experience and success in medical device commercialization, helping founders and CEOs implement actionable go-to-market strategies that drive adoption and build company value.
Dr. Paula Miliani de Marval
Senior Director of ResearchPaula is a highly motivated scientific director with deep knowledge of cancer biology and oncology drug discovery, guiding the research behind LifePulse's clinical evidence and human oncology roadmap.
Tariq Shah
Director, Veterinary Oncology / GM Animal HealthTariq brings two decades of experience in animal health with a concentration in medical oncology, and a proven track record developing the veterinary oncology market.
Chelsea Tripp, DVM, DACVIM (Oncology)
Advisory BoardDr. Tripp is one of the most recognized experts in this technology within veterinary medicine, a sought-after speaker and key opinion leader who also advised on the VetPulse 2000's clinical design.
Alexander Fleming, MD
Advisory BoardA physician by training, Dr. Fleming is the founder of Kinexum, a highly respected FDA translational guidance firm based in Washington, D.C., supporting LifePulse's regulatory strategy.
LifePulse's board pairs deep oncology and capital-markets experience with the operating leadership driving the company day to day.
Dr. C. Richard Piazza
Executive ChairmanRichard is a serial healthcare CEO with more than 30 years leading device, biotech, and provider companies, having raised over $120M in institutional and angel capital. Former CEO of Vital Therapies (NASDAQ: VTL), he led the divestiture of SoloPak Pharmaceuticals to Smith & Nephew, and brings a close relationship with MD Anderson.
Gary Strange
Chairman Emeritus & Founder, DirectorGary founded LifePulse in 2018 and brings more than 30 years of experience in business leadership. He continues to guide company strategy as it scales veterinary revenue and advances toward FDA clearance and a future CE mark.
Donald G. Fell
DirectorDon sits on the boards of several Nasdaq-listed companies and brings a wealth of business acumen to LifePulse, alongside a long career in economics education at institutions including the University of South Florida.
Gerald Sokol, MD
DirectorDr. Sokol is a practicing physician board-certified in medical oncology, radiation oncology, and internal medicine, recognized internationally for advancing skin cancer treatment. MD from Indiana University; residency and fellowship training at Harvard Medical School / Massachusetts General Hospital, Temple University Hospital, and the U.S. Public Health Service Hospital in affiliation with Johns Hopkins, the University of Maryland, and the National Cancer Institute.
Greg Walters
DirectorGreg is a former securities attorney and serial entrepreneur, including having taken a medical device through FDA approval — directly relevant to LifePulse's own regulatory path.
Trinity Bui
DirectorTrinity has worked in finance and investment for 39 years and is the founder of TFIC. She holds an MBA in Finance and joined the board as part of its recent governance expansion.
Bob Roda, CEO, also serves as a Director — see his full bio under Leadership.
Every design and business decision at LifePulse is weighed against patient welfare, transparency, and responsible growth — for animals and humans alike.
Patient welfare, first
Every design choice in IntelliPulse starts from reducing harm to the patient — animal or human. Operating at less than half the energy of legacy systems exists specifically to lower pain scores and reduce reliance on heavy anesthesia.
Precision over guesswork
Tumor Sense technology exists to prevent overtreatment as much as undertreatment — real-time impedance feedback replaces a single blind pulse and hope.
Transparent evidence
We report clinical evidence, including both favorable and limiting results, transparently to clinicians, regulators, and partners — not just the highlights.
Sustainable by design
The VetPulse platform is a durable, reusable capital device paired with single-use consumables sized to the procedure — designed to minimize waste relative to disposable-only systems.
As LifePulse scales manufacturing with its distribution partners, we're committed to responsible sourcing and data-privacy practices — including GDPR- and CCPA-aligned handling of clinical and customer data — as standard, not an afterthought.
A dual-market strategy: veterinary success funding human entry
Current raise
LifePulse is raising a $1.5M secured note to reach 2026 breakeven and prepare the company for acquisition. For the full investor deck and financial model, contact our team directly.
Request Investor MaterialsPlanned exit strategy
- Near term: veterinary oncology scale-up, lower risk, targeting $30–50M revenue over 5–6 years
- Medium term: 510(k) clearance and a small-N human safety trial, moderate risk, 12–15 months
- Longer term: strategic acquisition positioning with veterinary revenue, partnerships, and regulatory clarity in place
This overview does not constitute an offer to sell, or a solicitation of an offer to buy, any securities. Any offering LifePulse Corporation may make will be made only pursuant to a securities purchase agreement, and only to accredited investors. Statements, estimates, and projections reflect management's current assumptions, which may or may not prove correct; LifePulse makes no representation as to their accuracy.
Order consumables online
Electrode arrays, intratumoral chemotherapy kits, and gene electrotransfer consumables ship directly to your clinic. Capital equipment is handled by your account representative.
Photo pendingSingle-Use Electrode Arrays
The standard consumable for IntelliPulse procedures. Sterile, single-use, sized per procedure.
Photo pendingIntratumoral Chemotherapy Kit
Formulated delivery kit for intratumoral chemotherapy procedures using the IntelliPulse drug-delivery mode.
Photo pendingGene Electrotransfer Kit
Consumable kit supporting gene delivery procedures on the IntelliPulse multi-modal platform.
Photo pendingReplacement Handpiece Cable
Certified replacement cable for the VetPulse 2000 and IntelliPulse handpieces.
Photo pendingAblation Procedure Support Kit
Supporting materials for irreversible electroporation (ablation) procedures, including sterile field accessories.
VetPulse 2000 / IntelliPulse Platform
Capital equipment purchases are handled through a dedicated account manager, not online checkout.
Newsroom
Company milestones, partnerships, and research updates from across the LifePulse platform.
LifePulse announces distribution partnership with Patterson Veterinary
Scales manufacturing and distribution of the VetPulse 2000 platform across Patterson's veterinary network.
NIH/NCI awards $2M grant to fund veterinary melanoma study
Non-dilutive funding validates LifePulse's scientific approach and supports research relevant to the human oncology program.
25 IntelliPulse devices now deployed across U.S. veterinary oncology centers
Growing installed base drives recurring consumables revenue and expands the clinical evidence base.
LifePulse expands its Board of Directors
New directors bring additional public-company governance, oncology, and capital-markets experience.
For media inquiries, contact our team.
Build the next generation of cancer treatment with us
LifePulse is a small, fast-moving team spanning veterinary oncology, human research, and medical device engineering — based in Tampa Bay Medical Park, Florida.
Field Clinical Specialist, Veterinary Oncology
Support onboarding and clinical training for veterinary clinics adopting the VetPulse 2000 platform.
ApplyRegulatory Affairs Manager
Lead 510(k) submission preparation and FDA correspondence as LifePulse advances its human oncology program.
ApplyManufacturing Engineer
Support scaling of the VetPulse 2000 platform and disposable electrode array production with our manufacturing partners.
ApplyTerritory Sales Manager, Veterinary
Grow the installed base of VetPulse devices across an assigned U.S. territory, working alongside our Patterson Veterinary partnership.
ApplyDon't see the right role? Send us your resume — we're growing quickly.
Talk with the LifePulse team
Requesting a demo, ordering consumables at scale, or exploring a research or investment partnership — we'll route you to the right person.
Headquarters
LifePulse Corporation
Tampa Bay Medical Park
400 N Ashley Dr, Suite 1900
Tampa, FL 33602
Contact
(813) 352-1434
gary.strange@lifepulse.co
lpbsupport@lifepulsebio.com (veterinary support)